Clasificación en acciones
#16843
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in... Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Precio por acción
$3.31
Última sincronización: 2026-09-01
Capitalización bursátil
$271.03M
Comercio Oryzon Genomics S.A. (ORY)
Precio ORY con Capital del mercado a B
Capitalización de mercado de Oryzon Genomics S.A.(ORY)
Capitalización bursátil: $271.03M
A fecha de September 2026, Oryzon Genomics S.A. tiene una capitalización de mercado de $271.03M. Esto convierte a Oryzon Genomics S.A. en la 16843rd empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Oryzon Genomics S.A. desde 2015 hasta 2026
ORY en comparación con los más populares 5 títulos stocks
| Precio por ORY |
|
Activo B |
Capital del mercado en B |
Resultados |
|
|
|
|
$5.260T
|
+1,940,475.84%
|
|
|
|
|
$4.779T
|
+1,762,978.10%
|
|
|
|
|
$4.017T
|
+1,481,909.34%
|
|
|
|
|
$3.719T
|
+1,372,169.56%
|
|
|
|
|
$2.734T
|
+1,008,720.02%
|
